



AURORA 22/1

Medical Cannabis Product distributed in the UK

Active ingredient: Dominant: Cultivar:	Approx. 22% TH <1% CBD Sativa Delahaze	IC AURORA 22%THC <19	blüten
Ingredients:			
% 30 25 20 15 10 5 0 THC	CBD	- 18% - 17% - 13% - 13% Other - 39% Shown as a percentage of the total terp Percentages are averages over multiple	

Terpene ¹	Terpinolene	β-myrcene	a-pinene	β-pinene
Scent	sweet, fruity	woody, fruity	woody, spicy	woody, spicy

1. Russo E.B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology 163: 1344–1364.

AURORA 22/1

TITRATION GUIDE

- There is currently no uniform starting dose for cannabis products nor uniform dosing information.
- Patients are recommended to slowly titrate up to find their optimal dose for maximum therapeutic effects and minimal adverse effects.
- Timing of onset depends on mode of administration.

Onset and duration of effects for inhalation and oral adminstration²

	Inhalation		Oral administration	
Onset of Effect	(•)	Within seconds to minutes	Ŀ	Within 30 minutes to 2 hours
Peak Effects	Ŀ	Full effects peak within 30 minutes	Ŀ	Full effects peak within 4 hours
Duration of Effect	Ŀ	Up to 6 hours or longer	Ŀ	Up to 12 hours or longer

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard

> Adverse events should also be reported to: IPS Pharma | medicalcannabis@ipsspecials.com | 0800 644 0747



Aurora Medicine UK Limited | 5th Floor | 14-16 Dowgate Hill | London EC4R 2SU | United Kingdom

2. Minister of Health HC, Health Canada. Health Effects of Cannabis.; 2017.

Grow Pharma Limited | www.grow-pharma.com